Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that has also shown neuroprotective effects in experimental stroke models. However, while the neuroprotective efficacy of Exendin-4 has been thoroughly investigated if the pharmacological treatment starts before stroke, the therapeutic potential of the Exendin-4 if the treatment starts acutely after stroke has not been clearly determined. Further, a comparison of the neuroprotective efficacy in normal and aged diabetic mice has not been performed. Finally, the cellular mechanisms behind the efficacy of Exendin-4 have been only partially studied. The main objective of this study was to determine the neuroprotective efficacy of Exendin-4 in normal and aged...
Introduction: Stroke is caused from the occlusion of any cerebral artery leading to cerebral ischemi...
Aims: Type 2 diabetes is highly prevalent in the elderly population. Glucagon like Peptide-1 mimetic...
OBJECTIVE—The therapeutic potential of exendin-4, an agonist of the glucagon-like peptide-1 receptor...
<div><p>Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that...
Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that has als...
Background and Purpose: Glucagon-like peptide-1 (GLP-1) receptor activation decreases stroke risk in...
Traumatic brain injury represents a major public health issue that affects 1.7 million Americans eac...
Background: Chronic hyperglycemia-associated inflammation plays critical roles in disease initiation...
<p>Stroke volume at one week after 50 µg/kg (A) Ex-4 administration. Number of surviving neurons in ...
BACKGROUND: Chronic hyperglycemia-associated inflammation plays critical roles in disease initiation...
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointe...
Abstract Background Type 2 diabetes (T2D) is an independent risk factor for Alzheimer's disease (AD...
Background: Exendin-4 is a peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor, currentl...
OBJECTIVE—The aim of this study was to find an effective treatment for the genetic form of diabetes ...
Background: Exendin-4 is a peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor, currentl...
Introduction: Stroke is caused from the occlusion of any cerebral artery leading to cerebral ischemi...
Aims: Type 2 diabetes is highly prevalent in the elderly population. Glucagon like Peptide-1 mimetic...
OBJECTIVE—The therapeutic potential of exendin-4, an agonist of the glucagon-like peptide-1 receptor...
<div><p>Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that...
Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that has als...
Background and Purpose: Glucagon-like peptide-1 (GLP-1) receptor activation decreases stroke risk in...
Traumatic brain injury represents a major public health issue that affects 1.7 million Americans eac...
Background: Chronic hyperglycemia-associated inflammation plays critical roles in disease initiation...
<p>Stroke volume at one week after 50 µg/kg (A) Ex-4 administration. Number of surviving neurons in ...
BACKGROUND: Chronic hyperglycemia-associated inflammation plays critical roles in disease initiation...
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointe...
Abstract Background Type 2 diabetes (T2D) is an independent risk factor for Alzheimer's disease (AD...
Background: Exendin-4 is a peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor, currentl...
OBJECTIVE—The aim of this study was to find an effective treatment for the genetic form of diabetes ...
Background: Exendin-4 is a peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor, currentl...
Introduction: Stroke is caused from the occlusion of any cerebral artery leading to cerebral ischemi...
Aims: Type 2 diabetes is highly prevalent in the elderly population. Glucagon like Peptide-1 mimetic...
OBJECTIVE—The therapeutic potential of exendin-4, an agonist of the glucagon-like peptide-1 receptor...